• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Biogen sees flat 2024 sales, pick up in Alzheimer's drug demand

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 13, 2024 at 12:12: PM
via Biogen (BIIB.O), opens new tab on Tuesday forecast flat 2024 product revenue as top-selling drugs face tough competition and sales of newer treatments take off slowly, but said there are signs its new Alzheimer's drug is gaining traction.

article source
 

<



Similar threads

cafead
Biogen sees ‘encouraging’ trends for postpartum depression drug
Replies
0
Views
95
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Biogen CEO sees progress in launch of Alzheimer’s drug Leqembi
Replies
0
Views
117
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Biogen sees two phase 2 failures: In sciatica and in its lupus collaboration with UCB
Replies
0
Views
236
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Biogen to seek approval for high-dose version of SMA stalwart Spinraza after trial win
Replies
0
Views
16
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Eisai, Biogen&#039;s Leqembi nabs UK nod, but reimbursement remains elusive
Replies
0
Views
33
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote